When paclitaxel is used as second-line therapy for classic Kaposi sarcoma progressive on anthracycline-based treatment, failure to achieve remission of KS lesions raises the question of what comes next. This protocol addresses the step taken after that failure.
Paclitaxel was deployed as second-line therapy in the setting of classic KS that had progressed on prior anthracycline treatment. When this approach does not achieve remission of Kaposi sarcoma lesions, further escalation is indicated.
At this stage, salvage chemotherapy is the direction of management. Several distinct regimens may be considered — selection depends on the specific clinical context. The complete structured protocol, including which agents apply and when, is available below.
DOI: 10.1111/ddg.14788
As a salvage treatment after anthracycline or paclitaxel therapy, oral etoposide, irinotecan, the previously used ABV regimen (adriamycin or doxorubicin with bleomycin and vincristine) as well as Gemcitabine may also be considered.
View source ↗